16 terminated. 16 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Terminated 16 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 1 | Terminated 1 |
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma CPI 613, Bendamustine - Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 6 | 2020-09-16 | 2025-05-02 |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Copanlisib, Rituximab, Bendamustine - Lymphoid Leukemia, Non-Hodgkin's Lymphoma | Phase 2 | Terminated | University of Washington | 1 | 2020-01-31 | 2022-04-11 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation Allogeneic Bone Marrow Transplantation, Bendamustine, Filgrastim-sndz - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2019-10-28 | 2026-04-15 |
| Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma Bendamustine, Obinutuzumab - Mantle Cell Lymphoma, Non-hodgkin Lymphoma | Phase 2 | Terminated | University of Wisconsin, Madison | 21 | 2017-09-29 | 2024-10-24 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 710 | 2016-05-25 | 2022-07-21 |
| Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting Brentuximab Vedotin, Bendamustine - Lymphatic Diseases | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 43 | 2015-12-23 | 2021-05-27 |
| Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Brentuximab Vedotin, Rituximab, Bendamustine - Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma | Phase 2 | Terminated | Seagen Inc. | 25 | 2015-10-01 | 2018-10-16 |
| BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) BeEAM - Follicular Lymphoma | Phase 2 | Terminated | Centre Leon Berard | 21 | 2014-07-09 | 2019-01-08 |
| Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma Bendamustine, Carfilzomib, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Suzanne Lentzsch, MD | 23 | 2013-11-01 | 2024-09-19 |
| Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma Bendamustine, Bortezomib - Multiple Myeloma | Phase 2 | Terminated | NYU Langone Health | 24 | 2011-09-01 | 2018-02-07 |
| Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma Bendamustine - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Loyola University | 3 | 2011-05-05 | 2018-07-10 |
| Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma Bendamustine, Doxorubicin, Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Sherif Farag, MB, BS | 32 | 2010-07-01 | 2023-10-06 |
| Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) Ofatumumab and Bendamustine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Terminated | Georgetown University | 10 | 2010-04-01 | 2015-12-15 |
| Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Lenalidomide, Fludarabine, Rituximab - Chronic Lymphocytic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 39 | 2009-05-06 | 2020-01-27 |
| Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma Bendamustine, Mitoxantrone, Rituximab - Follicular Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 14 | 2009-05-01 | 2020-04-03 |
| Bendamustine in Acute Leukemia and MDS Bendamustine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 27 | 2008-11-01 | 2012-12-04 |
Lymphoma, Non-Hodgkin (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Multiple Myeloma (4) · Lymphoma (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (2) · Neoplasms, Plasma Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Burkitt Lymphoma (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphatic Diseases (1) · Lymphoma, B-Cell, Marginal Zone (1)
M.D. Anderson Cancer Center (4) · Centre Leon Berard (1) · Fondazione Italiana Linfomi - ETS (1) · Georgetown University (1) · Loyola University (1) · NYU Langone Health (1) · Seagen Inc. (1) · Sherif Farag, MB, BS (1) · Suzanne Lentzsch, MD (1) · TG Therapeutics, Inc. (1) · University of Washington (1) · University of Wisconsin, Madison (1) · Wake Forest University Health Sciences (1)
United States (14) · Italy (3) · France (2) · Poland (2) · Spain (2) · United Kingdom (2) · Australia (1) · Czechia (1) · Israel (1) · Slovakia (1) · South Korea (1)
Amitabha Mazumder, MD (1) · Bruce Cheson, MD (1) · Hagop M. Kantarjian, M.D. (1) · Issa F Khouri (1) · Issa F. Khouri, MD, BS (1) · Julie Chang, MD (1) · Nathan Fowler, MD (1) · Owen A O'Connor, MD, PhD (1) · Rakhee Vaidya, M.B.B.S. (1) · Ryan Lynch (1) · Scott Smith, MD, PhD (1) · Sherif Farag, M.B., B.S. (1) · Suzanne Lentzsch, MD (1) · Thomas Manley, MD (1)
PMID 24925211, PMID 33683917, PMID 41671463
P30CA012197 (1)